• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services

    Helsinn Establishes New R&D Hub in the U.S.

    CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development

    How Can Automation Optimize Immunohistochemistry?
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Biosynth Carbosynth

    Aphena Pharma Solutions

    Kyongbo Pharmaceutical

    Vector Partners Limited

    Quotient Sciences
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Biosynth Carbosynth

    Aphena Pharma Solutions

    Kyongbo Pharmaceutical

    Vector Partners Limited

    Quotient Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Changing Prices in the Bio CMO Market

    A dynamic market for biopharmaceutical contract manufacturing services is seeing prices rise and fall

    Changing Prices in the Bio CMO Market
    Changing Prices in the Bio CMO Market
    Related CONTENT
    • Taros Chemicals GmbH & Co. KG
    • Sekisui
    • Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership
    • The Future of Continuous Bioprocessing
    • The Future of Continuous Bioprocessing
    William Downey , President, HighTech Business Decisions03.06.15
    Over the past two years, the change in prices for biopharmaceutical contract manufacturing services has been mixed. For mammalian cell culture production, prices for small-scale projects have dropped, while prices for medium-scale projects have increased. In addition, the prices charged by CMOs for ancillary services, e.g., process development, have also increased over the past two years. In the near-term, biotechnology companies expect to pay higher prices for raw materials, consumables, analytical and other consultative-type services. The expectation of higher prices for consultative-type services is consistent with the trends we have seen with FTE rates charged by CMOs for process development services.   

    The information and analysis for this article comes from HighTech Business Decisions’ latest report, “Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2013/2014.” This report is based on primary research from 27 respondents at pharmaceutical and biotechnology companies (“Users”) who outsource some or all of the production of biopharmaceuticals, and from 18 biopharmaceutical contract manufacturing organizations (CMOs). All respondents in this study are senior-level executives or scientists. This study focuses solely on biopharmaceutical manufacturing sold on a fee-for-service basis by CMOs. For purposes of our study, HighTech Business Decisions defines biopharmaceuticals as complex molecular structures created through the genetic manipulation of living cells or organisms used for therapeutics, diagnostics or vaccines. The respondent companies participating in this study are located in North America, Europe and Asia.

    Recent Price Changes
    Based on the observations from the respondents in our study, overall prices for biopharmaceutical contract manufacturing services show an upward trend. While a plurality of respondents observed stable prices over the past two years, more respondents reported higher prices versus lower prices. In total, 49% of the respondents in our study report stable prices, 31% of the respondents report higher prices, and 20% of the respondents report lower prices (Table I). For this analysis, we define stable prices as changes of 3% or less. We assume small price changes result from either currency fluctuations or general economy-wide inflation levels—not necessarily specific industry price changes. Further analysis of observed price changes by the two respondent groups, shows that Users observed more price increases than did CMOs. 

    Highlighting the differences in observed price changes between Users and CMOs, 52% of the Users observed stable prices, while 44% of the CMOs observed stable prices. Furthermore, 37% of the Users observed higher prices over the past two years, while just 22% of the CMOs observed higher prices over the same time period. Conversely, only 11% of the Users observed lower prices compared to 33% of the CMOs who observed lower prices. While the observations between Users and CMOs are different, these differences are not significant, based on the chi-square test for independence between the Users and CMOs. The chi-square test for independence shows a p-value of 0.17; therefore, we cannot reject the null hypothesis for independence. Thus, while there are some differences between Users’ and CMOs’ price observations, these differences are not significant.

    Although the two respondent groups’ observations regarding overall price changes are statistically similar, the observation of lower prices shows a significant difference between the two groups. Only 11% of the Users observed lower prices, while 33% of the CMOs observed lower prices over the past two years. The CMO respondent group was three times more likely to observe lower prices than the User respondent group. This difference is significant, as can be seen by the adjusted residual of 1.83, which is most likely the result of different project scales and product phases between Users and CMOs.

    Several respondents gave specific examples or details about their price observations. A few respondents mentioned lower prices are associated with either new CMOs, or CMOs using single-use technologies. Other respondents noted that greater demand for contract manufacturing services has resulted in higher prices. Similarly, other respondents note that consolidation and mergers have reduced excess capacity; thereby lessening the need to offer steep discounts in an effort to fill unused capacity.

    A few insightful comments from the biomanufacturing directors regarding the price changes for contract manufacturing services are given here:
    • “There has been consolidation in the industry that has driven prices up. Some small start-ups are offering lower level pricing, but the mainstream CMOs are increasing their prices.”

    – Pharmaceutical/Biotechnology Company

    • “Pricing for single-use has decreased more than 10%. Pricing for manufacturing in stainless steel has remained consistent for the past seven years.”

    – Pharmaceutical/Biotechnology Company

    • “Pricing has been stable for the last three or four years. There was a downturn around 2008/2009. Since then the volume of projects has been going up but balancing that, there are more CMOs and some CMOs are making large investments in infrastructure. Single-use bioreactors are making it easier to get into the industry.” 

    – Contract Manufacturing Organization


    GMP Production Price Changes
    The mixed observations about changes in prices observed by the two respondent groups can also be seen in the change in prices for mammalian cell culture production. From our current and past studies we collected detailed price information from both the Users and the CMOs for GMP manufacturing in order to evaluate current industry pricing. From our quantitative analysis of pricing, the per-batch prices for mammalian cell culture have declined for small-scale production and increased for medium-scale production over the past two years (Figure 1).

    The average per-batch price for small-scale mammalian cell culture production is down 8% from two years ago. While over the same period, the average per-batch price for medium-scale production is up 21% over the same time period. And the average price for large-scale production has stayed relatively flat; it is up 1%. As noted earlier, the lower prices for small-scale mammalian cell culture production most likely results from new CMOs entering the market coupled with the adoption of single-use technologies at these smaller scales. The higher batch prices for medium-scale production most likely results from consolidations and adjustments in industry capacity to better match supply with demand.

    FTE Rates
    Besides production prices, the respondents in this study also provided the annual FTE rates for the various consultative-type services provided by CMOs. These rates are for services using staffs in functions such as process development, manufacturing, quality, regulatory support, and project management. From the CMOs’ inputs, annual FTE rates for process development services range from less than $100,000 to greater than $400,000. The average annual FTE rate charged by CMOs for process development is $248,000, which is an increase of 19% from two years ago. This large increase in average FTE rates results from the distribution of FTE rates being more positively skewed in 2013 compared to 2011. From our analysis, there are fewer CMOs charging for process development services at the lowest FTE rate category, and more CMOs are charging at higher rate categories. As an example, in 2013, 75% of the CMOs charged an FTE rate of $350,000 or less, while in 2011, 78% of the CMOs charged an FTE rate of $300,000 or less.

    Future Expectations
    In addition to providing details about current prices paid for contract manufacturing services, the respondents from the pharmaceutical and biotechnology companies in our study also discussed their expectations about future price changes. Over the next two to three years, a majority of Users expect higher prices. The reasons for higher prices include higher demand for contract manufacturing services, greater regulatory and quality requirements being placed on CMOs, and general inflationary pressures.

    They expect higher demand over the next few years to increase industry capacity utilization rates and thus reduce excess supply.
    Currently, slightly more than half the Users (52%) are now experiencing higher prices or seeing proposed price increases from their CMOs. Additionally, about one-fifth of the Users (18%) expect to see higher prices in certain services and lower prices for other services offered by their CMOs, while approximately one-quarter (26%) of the Users expect stable prices in the future.

    In addition to sharing their expectations about future price changes, the Users also provided details about specific products or services that they expect to see future price changes (Figure 2). The Users expect to pay higher prices for raw materials and consultative-type services. They specifically mention higher prices for raw materials and consumables, stability and release testing, analytical services and technology transfer. Higher prices for raw materials and consumables were mentioned most often by the Users, while higher prices for consultative-type services correspond to the higher average FTE rates reported by the CMOs. On the other hand, the Users have a mixed outlook for changes in manufacturing prices. In this case, more Users expect to see lower prices than higher prices.   

    Below are comments from both pharmaceutical and biotechnology companies and CMO respondents regarding their future price expectations:
    • “We are seeing increased requirements for testing for adventitious agents but this is usually testing outsourced by the CMO so they pass through the costs to us so it is not really an increase from the CMO.”

    – Pharmaceutical/Biotechnology Company

    • “We’re seeing higher prices for ancillary services such as project management and supply chain distribution.”

    – Pharmaceutical/Biotechnology Company

    • “Materials costs seem to be higher, things like resins, chemicals, and components. Transportation costs are higher and sourcing takes more effort now because vendors are not keeping as much inventory on hand. It may be that we had very good agreements in the past and now vendors are realizing they need to charge more.”

    – Pharmaceutical/Biotechnology Company

    • “FTE rates are going up which will affect all services. The FTE inflation rate is higher in Asia than in the U.S. and Europe. The capacity utilization rate is increasing so we can expect prices to go up.”

    – Pharmaceutical/Biotechnology Company

    • “Raw materials, our vendors’ pricing is going up higher than inflation. It is not clear why, maybe because of consolidation among suppliers or maybe because of the cost of implementing quality systems. Testing pricing is stable, but we are doing more testing. Regulators and consultants at the biotechs are requesting the extra testing. There is a good database for different kinds of products now, tests that have proved to be useful, so the regulatory bodies expect them to be done.”

    – Contract Manufacturing Organization

    • “For any monopolistic situation pricing is higher, for example column materials. Consolidation at places like Thermo Fisher and Life Science Technologies are contributing to this monopolistic situation. Equipment maintenance costs are going up.  Suppliers realize customers are bound to them.”

    – Contract Manufacturing Organization


    Analysis
    An interesting observation can be seen from the changes in prices for both production and consultative-type services offered by CMOs. First, the lower prices for small-scale production and the expected higher costs for raw materials and consumables suggest that the benefits from adopting single-use production technologies will not accrue to the CMO itself. But rather the financial benefits of adopting single-use technologies will accrue to either the CMO’s supplier or client. The lower upfront capital cost of single-use production reduces the barriers of entry for new CMOs. As noted by a few respondents, there are more CMOs entering the market using disposable technologies. The lower entry barrier results in a more intensely competitive market creating greater price competition and lower margins for those CMOs that cannot effectively differentiate its service offerings. Thus we see lower prices for small-scale production where single-use technologies are being adopted. In addition, expected price increases for consumables and raw materials shows that larger raw material suppliers are also able to derive some of the financial benefits of using disposable technologies from their CMO customers. This is most likely the result of the limited bargaining power that smaller CMOs have with its raw material suppliers.

    The other observation pertains to higher FTE rates. The rates paid by the Users for consultative-type services have remained flat over the past two years, however, we see that average rates being charged by CMOs increasing dramatically over the past two years. The average rates are increasing because fewer CMOs charge rates at the lowest tier. These higher rates most likely reflect the narrowing salary differences between geographic areas. 

    Summary
    The market for biopharmaceutical contract manufacturing services is dynamic, and prices are both increasing and decreasing. Smaller-scale production prices have dropped over the past year, while mid-scale production prices have increased from two years ago. In addition, consultative-type service prices are continuing to increase. Some of these increases are the result of higher wage inflation in emerging markets compared to the wage inflation in developed markets. Overall, the pharmaceutical and biotechnology companies expect to pay higher prices for raw materials and consumables, and consultative-type services in the future. 


    William Downey, is president of HighTech Business Decisions—a market research and consulting firm that serves the pharmaceutical and biotechnology industry. HighTech Business Decisions closely follows and reports on the biopharmaceutical contract manufacturing industry with both private and public industry reports. Mr. Downey has published a number of articles covering various issues facing the biopharmaceutical contract manufacturing industry. Before joining HighTech Business Decisions, Mr. Downey held various executive positions in technical product marketing, strategic planning and finance at both public and private companies.
    Related Searches
    • Biomanufacturing
    • Process Development
    • CMO
    • Testing
    Suggested For You
    Taros Chemicals GmbH & Co. KG Taros Chemicals GmbH & Co. KG
    Sekisui Sekisui
    Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership
    The Future of Continuous Bioprocessing The Future of Continuous Bioprocessing
    The Future of Continuous Bioprocessing The Future of Continuous Bioprocessing
    Solubility Enhancement of Hydrophobic Drugs and APIs Using Hot Melt Extrusion Solubility Enhancement of Hydrophobic Drugs and APIs Using Hot Melt Extrusion
    Process Intensification: Understanding the Optimal Way to Maximize Productivity Process Intensification: Understanding the Optimal Way to Maximize Productivity
    Oakwood Labs Oakwood Labs
    Civica to Build an Essential Medicines Manufacturing Facility in Virginia Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    Life Science Success Podcast: Matt Hicks Life Science Success Podcast: Matt Hicks
    A Potential “Marriage” A Potential “Marriage”
    Opportunities in Synthetic Biology Opportunities in Synthetic Biology
    Financial Report: Lilly Financial Report: Lilly
    Accelerating R&D Trends Accelerating R&D Trends
    The Pandemic’s Become an Insurmountable Opportunity The Pandemic’s Become an Insurmountable Opportunity

    Related Content

    • Taros Chemicals GmbH & Co. KG

      ...
      Dimitrios Tzalis, Manager Executive Projects 12.07.21

    • Sekisui

      ...
      Jim Alferman, Associate Director, Business Development 10.13.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
      Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership

      Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership

      Ink multi-year development and manufacturing agreement for mRNA COVID-19 vaccine candidate, PTX-COVID19-B.
      09.14.21


    • Bioanalytical Services | Bioassay Development | Biologics, Proteins, Vaccines
      The Future of Continuous Bioprocessing

      The Future of Continuous Bioprocessing

      The modernization of advanced therapy manufacturing.
      Dr. Karoline Hahn, Senior Consultant for Advanced Therapies, KCR 06.02.21

    • Bioanalytical Services | Biologics, Proteins, Vaccines
      The Future of Continuous Bioprocessing

      The Future of Continuous Bioprocessing

      The Modernization of Advanced Therapy Manufacturing
      Dr. Karoline Hahn, Senior Consultant for Advanced Therapies, KCR 05.27.21

      Trending
      • How Can Automation Optimize Immunohistochemistry? | Contract Pharma
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Corealis CDMO Completes Deal With ArchiMed | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • CureVac, MyNEO Partner On Antigen Targets For MRNA-Cancer Vax Development | Contract Pharma
      Breaking News
      • iECURE Enters Agreement with Center for Breakthrough Medicines
      • CPDC Enters Clinical Manufacturing Deal with CellBion
      • Olon to Build New R&D Center in Italy
      • Hanmi Fine Chemical Launches CDMO Business
      • DFE Pharma Opens India CoE for Fast-Track Formulation Services
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      ICP Receives ASC Innovation Award for Spray Foam That Meets Changing Environmental Regulations
      Pylon Coatings Uses Polygiene Biomaster & Verimaster for Antimicrobial Surface Protection
      Sto Corp. Recognized with Multiple Honors at the EIFS Hero Awards
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      New Breast Implant Surgery Guidelines to Enhance Patient Safety
      Rhythm Management Group Debuts RhythmSynergy Tech Platform
      FDA Approves Trial Completion for Virtual Incision's MIRA Platform
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Olon to Build New R&D Center in Italy
      Hanmi Fine Chemical Launches CDMO Business
      DFE Pharma Opens India CoE for Fast-Track Formulation Services
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      K-Beauty Brand Siita Shares Plastic Decomposition Technology with the Beauty Industry
      Shellworks Raises $6.2 Million in Seed Funding
      Ulta Beauty Reports Record First Quarter 2022 Results
      Happi

      Latest Breaking News From Happi

      Honeywell Addresses Critical Issues Such as Sustainability, Workforce Training and Digitalization
      Monat Global Wins Four Stevie Awards in the 20th Annual American Business Awards
      Coty Expands Vegan Beauty Portfolio With New Rimmel Mascara
      Ink World

      Latest Breaking News From Ink World

      UK-Based Caps Cases Installs World’s First EFI Nozomi 14000 LED Digital Corrugated Press
      Sonoco Announces Transition of Chief Financial Officer
      Azelis Expands Presence in India
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Labelexpo Asia 2022 postponed
      Teklynx software helps Top Clean Injection validate labels
      Zeller+Gmelin named Berry Global’s 2021 Ink Supplier of the Year
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Toetal Solutions Raises $1.02 Million in New Financing
      ManaMed's ManaSport Wearable Ultrasound Earns FDA Nod
      Ekso Bionics Names Jerome Wong as Interim CFO
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      onsemi Recognized by Fortune 500 for Its Transformation Journey
      LG Display Presents AI-Driven NFT Artwork on Transparent OLED
      Joe Stockunas Joins SEMI as Americas President

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login